




RealRate

PHARMACEUTICAL 2022

Oncosec Medical Inc
Rank 310 of 471

oncosec
IMMUNOTHERAPIES



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Oncosec Medical Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncosec Medical Inc compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 13% points. The greatest weakness of Oncosec Medical Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 231%, being 44% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	49,179
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,962
Liabilities, Non-Current	5,238
Other Assets	6,168
Other Compr. Net Income	-60
Other Expenses	-2,396
Other Liabilities	5,000
Other Net Income	816
Other Revenues	0
Property and Equipment	929
Research and Development	34,098
Selling, General and Administrative Expense	14,282

Output Variable	Value in 1000 USD
Assets	56,276
Liabilities	18,200
Expenses	45,984
Revenues	0
Stockholders Equity	38,076
Net Income	-45,168
Comprehensive Net Income	-45,198
BaseVar	60,668
ECR before LimitedLiability	102%
Economic Capital Ratio	231%